Swedish Orphan Biovitrum and BL&H Co., Ltd sign distribution agreement for South Korea
Stockholm, Sweden and Seoul, South Korea - January 11, 2011 - Swedish Orphan
Biovitrum (STO: SOBI) and BL&H Co., Ltd. (Better Life & Health) today signed a
distribution agreement for the products Orfadin and Kepivance in South Korea.
BL&H will pay Swedish Orphan Biovitrum (Sobi) an undisclosed transfer price for
the products and will be responsible for registering the products in South
Korea.
Since, the South Korean Food and Drug Administration registration process is
adapted to products already approved by the FDA or EMA, a registration and price
reimbursement can be expected approximately one year from application. Sales on
a named patient basis can be initiated already during 2011.
"We are very pleased to initiate a partnership with Sobi," said Dong Chul Roh,
CEO of BL&H. "There is an unmet medical need for these products in South Korea,
and we believe that we will be able to successfully provide Orfadin and
Kepivance to patients in this region."
"We are very excited about the possibility to work with BL&H Co., Ltd. on
providing Orfadin and Kepivance to patients who need these innovative products
in South Korea. BL&H has extensive experience and expertise in the sales and
marketing of rare disease products in South Korea and we look forward to a
fruitful partnership." said Anders Edvell, Head of Marketing and Sales at
Swedish Orphan Biovitrum.
About Orfadin(TM
)There are around 700 known children throughout the world with the hereditary
disease tyrosinaemia type 1 (HT-1). The disease is caused by a genetic disorder
which means that the patient breaks down the amino acid tyrosine to toxic
metabolites. HT-1 primarily affects the liver, which ceases to function. The
disease exists in several forms. The acute form usually leads to death prior to
the child's first birthday if untreated. There is also a more chronic form of
the disease, which is also usually fatal.
By blocking an enzyme, Orfadin causes the amino acid tyrosine to be broken down
in a way which is harmless to the body. Untreated, the risk of dying in the
disease is up to 80 per cent while the patients who are treated with Orfadin
together with a certain diet have a survival rate of over 90 per cent.
About Kepivance® (palifermin)
Kepivance® is indicated to decrease the incidence and duration of severe oral
mucositis in patients with hematologic malignancies receiving myelotoxic therapy
requiring hematopoietic stem cell support. Information about Kepivance® can be
found at:http://www.kepivance.com/
Healthcare professionals should refer to national labeling texts.
About BL&H Co., Ltd.
BL&H is a privately owned pharmaceutical company based in South Korea. BL&H was
established in 1999 with the aim of becoming a leader in the delivery of
pharmaceuticals and services that fulfill unmet medical needs in the Korean
market. BL&H specializes in hospital-based products in hematology, oncology,
rheumatology and respiratory medicines. The management team has extensive
experience in the pharmaceutical and healthcare sectors and in bringing
specialty products to market.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease patients
with high medical needs. The portfolio consists of about 60 marketed products
and an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and
inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues
2009e of about 2 BSEK and approximately 500 employees. The head office is
located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm.
For more information please visitwww.sobi.com.
For more information please contact: Swedish Orphan Biovitrum AB (publ):
Anders Edvell, VP Marketing and Sales
Phone. +46 70 544 6126
Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on January 11, 2011 at 8:30 a.m. CET.